arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2012-18-3-255-266arthyper-1707Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESАртериальное давление, показатели липидного спектра и полиморфизмы генов аполипопротеина А1 и параоксоназы 1-го типа у больных абдоминальным ожирениемBlood pressure, lipid levels and apolipoprotein A1 and paraoxonase 1 gene polymorphisms in patients with abdominal obesityАн-НахарХ. ..An-HaharH. ..noemail@neicon.ruБольшаковаО. О.BolshakovaO. O.bolshakova@almazovcentre.ruБеляеваО. Д.BelyaevaO. D.noemail@neicon.ruБерковичО. А.BerkovichO. A.noemail@neicon.ruЛарионоваВ. И.LarionovaV. I.noemail@neicon.ruБарановаЕ. И.BaranovaE. I.noemail@neicon.ruГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздравсоцразвития РФРоссияvlov St Petersburg State Medical University, St PetersburgRussian FederationФГБУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова» Минздравсоцразвития РФРоссияAlmazov Federal Heart, Blood and Endocrinology Centre, St PetersburgRussian FederationГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова» Минздравсоцразвития РФРоссияvlov St Petersburg State Medical University, St PetersburgRussian FederationГБОУ ВПО «Санкт-Петербургская педиатрическая медицинская академия» Минздравсоцразвития РФРоссияSt Petersburg State Pediatric Medical AcademyRussian FederationГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздравсоцразвития РФ; ФГБУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова» Минздравсоцразвития РФРоссияvlov St Petersburg State Medical University, St Petersburg; Almazov Federal Heart, Blood and Endocrinology Centre, St PetersburgRussian Federation201228062012183255266Copyright © Ан-Нахар Х..., Большакова О.О., Беляева О.Д., Беркович О.А., Ларионова В.И., Баранова Е.И., 20122012Ан-Нахар Х..., Большакова О.О., Беляева О.Д., Беркович О.А., Ларионова В.И., Баранова Е.И.An-Hahar H..., Bolshakova O.O., Belyaeva O.D., Berkovich O.A., Larionova V.I., Baranova E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1707

Цель исследования — изучение G-75A и C+83T полиморфизмов гена аполипопротеина А1 (APOA1) и Q192R полиморфизма гена параоксоназы 1-го типа (PON1) и их взаимосвязь с уровнем артериального давления и показателями липидного обмена у больных абдоминальным ожирением. Материалы и методы. Обследованы 222 больных абдоминальным ожирением (57 мужчин и 165 женщин), жители Санкт-Петербурга. Результаты. Выявлена высокая встречаемость артериальной гипертензии (61 %) и различных видов дислипидемий. Проанализирована частота аллелей генов аполипопротеина А1 и параоксоназы 1-го типа у больных абдоминальным ожирением. Представлены данные относительно ген-генных взаимодействий и уровня артериального давления, выраженности ожирения и изменений липидного профиля в обследованной группе больных.

Objective. To evaluate G-75A and C+83T polymorphisms of apolipoprotein A1 gene and Q192R polymorphism of paraoxonase 1 gene and their association with blood pressure and lipid levels in patients with abdominal obesity. Design and methods. We examined 222 obese patients (57 males and 165 females), residents of St Petersburg, Russian Federation. Results. High incidence of arterial hypertension (61 %) and dyslipidemia of different types was revealed. The frequency of different alleles of apolipoprotein A1 and paraoxonase 1 genes was analyzed. The results of gene-gene interactions and their associations with blood pressure, obesity and lipids profiles are presented.

абдоминальное ожирениеметаболический синдромG-75A и C+83T полиморфизм гена аполипопротеина А1Q192R полиморфизм гена параоксоназыabdominal obesitymetabolic syndromeG-75A and C+83T polymorphisms of apolipoprotein A1 geneQ192R polymorphism of paraoxonase 1 geneReferencesAekplakom W., Mo-Suwan L. Prevalence of obesity in Thailand // Obes. Rev. — 2009. — Vol. 10, № 6. — 589-592.Aekplakom W., Mo-Suwan L. Prevalence of obesity in Thailand // Obes. Rev. — 2009. — Vol. 10, № 6. — 589-592.Despres J.P. Cardiovascular disease under the influence of excess visceral fat // Crit. Pathw. Cardiol. — 2007. — Vol. 6, № 2. — Р. 51-59.Despres J.P. Cardiovascular disease under the influence of excess visceral fat // Crit. Pathw. Cardiol. — 2007. — Vol. 6, № 2. — Р. 51-59.Kathiresan S. Lp(a) lipoprotein redux-from curious molecule to causal risk factor // N. Engl. J. Med. — 2009. — Vol. 361, № 26. — Р. 2573-2574.Kathiresan S. Lp(a) lipoprotein redux-from curious molecule to causal risk factor // N. Engl. J. Med. — 2009. — Vol. 361, № 26. — Р. 2573-2574.Lee Y.H., Choi S.H., Lee K.W., Kim D.J. Apolipoprotein B/ A1 ratio is associated with free androgen index and visceral adiposity and may be an indicator of metabolic syndrome in male children and adolescents // Clin. Endocrinol. (Oxf). — 2011. — Vol. 74, № 5. — Р. 579-586.Lee Y.H., Choi S.H., Lee K.W., Kim D.J. Apolipoprotein B/ A1 ratio is associated with free androgen index and visceral adiposity and may be an indicator of metabolic syndrome in male children and adolescents // Clin. Endocrinol. (Oxf). — 2011. — Vol. 74, № 5. — Р. 579-586.Gupta N., Gill K., Singh S. Paraoxonases: structure, gene polymorphism and role in coronary artery disease // Indian J. Med. Res. — 2009. — Vol. 130, № 4. — Р. 361-368.Gupta N., Gill K., Singh S. Paraoxonases: structure, gene polymorphism and role in coronary artery disease // Indian J. Med. Res. — 2009. — Vol. 130, № 4. — Р. 361-368.Mendoza M.I., Dos Res R.P., Freitas A.I. et al. Interaction of paraoxonase-192 polymorphism with low HDL-cholesterol in coronary artery disease risk // Rev. Port. Cardiol. — 2010. — Vol. 29, № 4. — P. 571-580.Mendoza M.I., Dos Res R.P., Freitas A.I. et al. Interaction of paraoxonase-192 polymorphism with low HDL-cholesterol in coronary artery disease risk // Rev. Port. Cardiol. — 2010. — Vol. 29, № 4. — P. 571-580.Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family // Genomics. — 1996. — Vol. 33, № 3. — Р. 498-507.Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family // Genomics. — 1996. — Vol. 33, № 3. — Р. 498-507.Hegele R.A. Paraoxonase genes and disease // Ann. Int. Med. — 1999. — Vol. 31, № 3. — Р. 217-224.Hegele R.A. Paraoxonase genes and disease // Ann. Int. Med. — 1999. — Vol. 31, № 3. — Р. 217-224.Aviram M., Hardak E., Vaya J. et al. Human serum paraoxo-nase (PON) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities // Circulation. — 2000. — Vol. 101, № 21. — Р. 2510-2517.Aviram M., Hardak E., Vaya J. et al. Human serum paraoxo-nase (PON) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities // Circulation. — 2000. — Vol. 101, № 21. — Р. 2510-2517.Aviram M., Rosenblat M., Bisgaier C.L. et al... Paraoxo-nase inhibits high-density lipoprotein oxidation and preserves its functions // J. Clin. Invest. — 1998. — Vol. 101, № 8. — Р. 1581-1590.Aviram M., Rosenblat M., Bisgaier C.L. et al... Paraoxo-nase inhibits high-density lipoprotein oxidation and preserves its functions // J. Clin. Invest. — 1998. — Vol. 101, № 8. — Р. 1581-1590.Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis // Arterioscler. Thromb. Vasc. Biol. — 2001. — Vol. 21, № 4. — Р. 473-480.Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis // Arterioscler. Thromb. Vasc. Biol. — 2001. — Vol. 21, № 4. — Р. 473-480.Rodrigo L., Mackness B., Durrington P.N, Hernandez A., Mackness M.I. Hydrolysis of platelet-activating factor by human serum paraoxonase // Biochem. J. — 2001. — Vol. 354, Pt. 1. — P. 1-7.Rodrigo L., Mackness B., Durrington P.N, Hernandez A., Mackness M.I. Hydrolysis of platelet-activating factor by human serum paraoxonase // Biochem. J. — 2001. — Vol. 354, Pt. 1. — P. 1-7.Billecke S., Draganov D., Counsell R. et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters // Drug Metab. Dispos. — 2000. — Vol. 28, № 11. — P. 1335-1342.Billecke S., Draganov D., Counsell R. et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters // Drug Metab. Dispos. — 2000. — Vol. 28, № 11. — P. 1335-1342.Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation // J. Biol. Chem. — 2000. — Vol. 275, № 6. — P. 3957-3962.Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation // J. Biol. Chem. — 2000. — Vol. 275, № 6. — P. 3957-3962.Getz G.S., Reardon C.A. Paraoxonase, a cardioprotective enzyme: continuing issues // Curr. Opin. Lipidol. — 2004. — Vol. 15, № 3. — P. 261-266.Getz G.S., Reardon C.A. Paraoxonase, a cardioprotective enzyme: continuing issues // Curr. Opin. Lipidol. — 2004. — Vol. 15, № 3. — P. 261-266.Aviram M., Rosenblat M. Paraoxonases and cardiovascular diseases: Pharmacological and nutritional influences // Curr. Opin. Lipidol. — 2005. — Vol. 16, № 4. — P. 393-399.Aviram M., Rosenblat M. Paraoxonases and cardiovascular diseases: Pharmacological and nutritional influences // Curr. Opin. Lipidol. — 2005. — Vol. 16, № 4. — P. 393-399.James R.W., Deakin S.P. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability and activity // Free Radic. Biol. Med. — 2004. — Vol. 37, № 12. — P. 1986-1994.James R.W., Deakin S.P. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability and activity // Free Radic. Biol. Med. — 2004. — Vol. 37, № 12. — P. 1986-1994.Kaplan N., Aviram M. Oxidized low density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase // Clin. Chem. Lab. Med. — 1999. — Vol. 37, № 8. — P. 777-787.Kaplan N., Aviram M. Oxidized low density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase // Clin. Chem. Lab. Med. — 1999. — Vol. 37, № 8. — P. 777-787.Ticozzi N., LeClerc A.L., Keagle PJ. et al. Paraoxonase gene mutations in amyotrophic lateral sclerosis // Ann. Neurol. — 2010. — Vol. 68, № 1. — Р. 102-107.Ticozzi N., LeClerc A.L., Keagle PJ. et al. Paraoxonase gene mutations in amyotrophic lateral sclerosis // Ann. Neurol. — 2010. — Vol. 68, № 1. — Р. 102-107.Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism // Nat. Genet. — 1993. — Vol. 3, № 1. — P. 73-76.Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism // Nat. Genet. — 1993. — Vol. 3, № 1. — P. 73-76.Talmud P.J., Ye S., Humphries S.E. Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: the European Atherosclerosis Research Study // Genet. Epidemiol. — 1994. — Vol. 11, № 3. — P. 265-280.Talmud P.J., Ye S., Humphries S.E. Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: the European Atherosclerosis Research Study // Genet. Epidemiol. — 1994. — Vol. 11, № 3. — P. 265-280.Reguero J.R., Cubero G.I., Batalla A. et al. Apolipoprotein A1 gene polymorphisms and risk of early coronary disease // Cardiology. — 1998. — Vol. 90, № 3. — Р. 231-235.Reguero J.R., Cubero G.I., Batalla A. et al. Apolipoprotein A1 gene polymorphisms and risk of early coronary disease // Cardiology. — 1998. — Vol. 90, № 3. — Р. 231-235.Pulkkinen A., Viitanen L., Kareinen A. et al. MspI polymorphism at +83 bp in intron 1 of the human apolipoprotein A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease // Diabetes Care. — 2000. — Vol. 23, № 6. — Р. 91-795.Pulkkinen A., Viitanen L., Kareinen A. et al. MspI polymorphism at +83 bp in intron 1 of the human apolipoprotein A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease // Diabetes Care. — 2000. — Vol. 23, № 6. — Р. 91-795.Dawar R., Gurtoo A., Singh R. Apolipoprotein A1 gene polymorphism (G-75A and C+83T) in patients with myocardial infarction: a pilot study in a north Indian population // Am. J. Clin. Pathol. — 2010. — Vol. 134, № 2. — Р. 249-255.Dawar R., Gurtoo A., Singh R. Apolipoprotein A1 gene polymorphism (G-75A and C+83T) in patients with myocardial infarction: a pilot study in a north Indian population // Am. J. Clin. Pathol. — 2010. — Vol. 134, № 2. — Р. 249-255.Sorkin S.C., Forestiero F.J., Hirata M.H. et al. APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals // Clin. Chem. Lab. Med. — 2005. — Vol. 43, № 12. — Р. 1339-1345.Sorkin S.C., Forestiero F.J., Hirata M.H. et al. APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals // Clin. Chem. Lab. Med. — 2005. — Vol. 43, № 12. — Р. 1339-1345.Rice N., Bandinelli S., Corsi A. et al. The paraoxonase (PON1) Q192R polymorphism is not associated with poor health status or depression in the ELSA or InCHIANTI studies // Int. J. Epidemiol. — 2009. — Vol. 38, № 5. — P. 1374-1379.Rice N., Bandinelli S., Corsi A. et al. The paraoxonase (PON1) Q192R polymorphism is not associated with poor health status or depression in the ELSA or InCHIANTI studies // Int. J. Epidemiol. — 2009. — Vol. 38, № 5. — P. 1374-1379.Birjmohun R.S., Vergeer M., Stroes E.S.G. et al. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study // PLoS One. — 2009. — Vol. 4, № 8. — P. e6809.Birjmohun R.S., Vergeer M., Stroes E.S.G. et al. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study // PLoS One. — 2009. — Vol. 4, № 8. — P. e6809.Koncsos P., Seres I., Harangi M. et al. Human paraoxo-nase-1 activity in childhood obesity and its relation to leptin and adiponectin levels // Pediatr. Res. — 2010. — Vol. 67, № 3. — P. 309-313.Koncsos P., Seres I., Harangi M. et al. Human paraoxo-nase-1 activity in childhood obesity and its relation to leptin and adiponectin levels // Pediatr. Res. — 2010. — Vol. 67, № 3. — P. 309-313.Kougias P., Chai H., Lin P.H. et al. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease // J. Surg. Res. — 2005. — Vol. 126, № 1. — Р. 121-129.Kougias P., Chai H., Lin P.H. et al. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease // J. Surg. Res. — 2005. — Vol. 126, № 1. — Р. 121-129.Bajnok L., Seres I., Varga Z. et al. Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals // Metabolism. — 2007. — Vol. 56, № 11. — Р. 1542-1549.Bajnok L., Seres I., Varga Z. et al. Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals // Metabolism. — 2007. — Vol. 56, № 11. — Р. 1542-1549.Nishio E., Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme’s free thiols // Biochem. Biophys. Res. Commun. — 1997. — Vol. 236, № 2. — P. 289-293.Nishio E., Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme’s free thiols // Biochem. Biophys. Res. Commun. — 1997. — Vol. 236, № 2. — P. 289-293.Dirican M., Akca R., Sarandol E., Dilek K. Serum paraoxo-nase activity in uremic predialysis and hemodialysis patients // J. Nephrol. — 2004. — Vol. 17, № 6. — Р 813-818.Dirican M., Akca R., Sarandol E., Dilek K. Serum paraoxo-nase activity in uremic predialysis and hemodialysis patients // J. Nephrol. — 2004. — Vol. 17, № 6. — Р 813-818.Deakin S., Leviev I., Gomaraschi M., Calabresi L., Fran-ceschini G., James R.W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism // J. Biol. Chem. — 2002. — Vol. 277, № 6. — Р 4301-4308.Deakin S., Leviev I., Gomaraschi M., Calabresi L., Fran-ceschini G., James R.W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism // J. Biol. Chem. — 2002. — Vol. 277, № 6. — Р 4301-4308.van Himbergen T.M., Roest M., de Graaf J. et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia // J. Lipid Res. — 2005. — Vol. 46, № 3. — Р 445-451.van Himbergen T.M., Roest M., de Graaf J. et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia // J. Lipid Res. — 2005. — Vol. 46, № 3. — Р 445-451.Agrawal S., Tripathi G., Prajnya R. et al. Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians // Indian J. Med. Sci. — 2009. — Vol. 63, № 8. — P. 335-344.Agrawal S., Tripathi G., Prajnya R. et al. Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians // Indian J. Med. Sci. — 2009. — Vol. 63, № 8. — P. 335-344.Banerjee I. Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysis // Eur. J. Epidemiol. — 2010. — Vol. 25, № 7. — P. 449-458.Banerjee I. Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysis // Eur. J. Epidemiol. — 2010. — Vol. 25, № 7. — P. 449-458.Garin M.C., James R.W., Dussoix P. et al. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes // J. Clin. Invest. — 1997. — Vol. 99, № 1. — P. 62-66.Garin M.C., James R.W., Dussoix P. et al. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes // J. Clin. Invest. — 1997. — Vol. 99, № 1. — P. 62-66.

The authors declare that there are no conflicts of interest present.